PepKon

Executive Summary

PepKon is a French biotechnology company founded in 2018 and based in Paris, specializing in first-in-class therapeutic peptides for oncology. Its platform designs peptides that mimic the cell-binding domain of thrombospondin-1 (TSP-1) to target the CD47 pathway, thereby inducing immunogenic cell death in cancer cells. The lead candidate, PKT16, is being developed for hematological malignancies and solid tumors. Currently in the pre-clinical stage, PepKon aims to advance PKT16 toward clinical trials. The company has not disclosed total funding or valuation, and its technology represents a novel approach to cancer immunotherapy by leveraging the CD47-SIRPα axis. With a focus on both hematological and solid tumors, PepKon targets a large market opportunity, though it remains at an early development phase with significant technical and regulatory risks ahead.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for PKT1660% success
• Q2 2027Series A Financing Round50% success
• H2 2027Licensing or Partnership Agreement for CD47 Platform40% success